Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D1.92 - Optimizing Aspirin Oral Provocation Testing in Suspected NSAID Hypersensitivity: A Real-World Protocol Analysis
D1.90 - Soft Tissue Loss Due to Allergic Reaction to Ahesive System during Orthodontic Treatment: A Case Report
D1.91 - Characterization of Bet v1 Sensitized Patients in Madrid: A Real Life Study
D1.93 - Isolated Generalized Pruritus Associated with SGLT2 Inhibitors: A Case Series with Negative Allergy Work-up
D1.94 - Vancomycin- and Meropenem-Induced DRESS Confirmed by the Lymphocyte Transformation Test: A Synergistic Effect in Severe Drug Reactions
D1.95 - Utility and safety of Patch Testing in anti-epileptic Induced DRESS: Diagnostic sensitivity and cross-reactivity profiling
D1.96 - Assessment of sensitivity to Lipid Transfer Proteins in allergic patients in the Republic of Moldova
D1.98 - Comparative Evaluation of Basal Serum Tryptase Determinants: Differential Impact of KIT D816V Allelic Load and HaT Gene Copy Number
D1.99 - Allergic contact dermatitis caused by Trofoblastin
D1.100 - Deciphering Multiple Drug Allergy syndrome: True Allergy or Pro-inflammatory Response ?
D1.101 - Colchicine-induced hepatitis: a case of drug interaction involving rivaroxaban
D1.102 - Furosemide-induced erythroderma: a diagnosis to consider
D1.103 - Successful Class Switching of SGLT2 Inhibitors Following Empagliflozin-Induced Maculopapular Exanthema: A Case Report
D1.97 - To FeNO or Not to FeNO: Is It a Practical Tool in Daily Management of Chronic Cough?
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download